Mesoblast Limited (MESO)

NASDAQ: MESO · IEX Real-Time Price · USD
2.55
-0.04 (-1.74%)
Sep 30, 2022 4:00 PM EDT - Market closed
-1.74%
Market Cap 373.96M
Revenue (ttm) 10.21M
Net Income (ttm) -91.35M
Shares Out 146.94M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE 833.33
Dividend n/a
Ex-Dividend Date n/a
Volume 92,965
Open 2.56
Previous Close 2.59
Day's Range 2.53 - 2.69
52-Week Range 2.14 - 7.28
Beta 2.55
Analysts Buy
Price Target 8.36 (+228.5%)
Earnings Date Aug 30, 2022

About MESO

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammato... [Read more...]

Industry Biotechnology
Founded 2004
CEO Silviu Itescu
Employees 77
Stock Exchange NASDAQ
Ticker Symbol MESO
Full Company Profile

Financial Performance

In 2022, Mesoblast's revenue was $10.21 million, an increase of 36.99% compared to the previous year's $7.46 million. Losses were -$91.35 million, -7.55% less than in 2021.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MESO stock is "Buy." The 12-month stock price forecast is 8.36, which is an increase of 228.49% from the latest price.

Price Target
$8.36
(228.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and opera...

1 month ago - GlobeNewsWire

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational...

1 month ago - GlobeNewsWire

Jane Bell Joins Mesoblast Board

NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane...

1 month ago - GlobeNewsWire

Appendix 4C Quarterly Activity Report

Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022 Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022

2 months ago - GlobeNewsWire

Rexlemestrocel-L to be Highlighted at Maxim's Panel on Late-Stage Advancements in Heart Failure Therapeutics and Mana...

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its...

2 months ago - GlobeNewsWire

Mesoblast Key Opinion Leader Event Series for Investors & Analysts

Chronic Low Back Pain due to Degenerative Disc Disease Chronic Low Back Pain due to Degenerative Disc Disease

3 months ago - GlobeNewsWire

Operational Highlights and Financial Results for the Period Ended March 31, 2022

Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission

4 months ago - GlobeNewsWire

Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board

NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R. Krause, M....

6 months ago - GlobeNewsWire

Operational Highlights and Financial Results for the Period Ended December 31, 2021

Mesoblast Prepares for Resubmission of Biologics License Application Mesoblast Prepares for Resubmission of Biologics License Application

7 months ago - GlobeNewsWire

Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn's Colitis After Direct Injec...

Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn's and Colitis Organisation (ECCO) Results of First Patient Cohort from Randomized Controlled Stud...

7 months ago - GlobeNewsWire

Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment of D...

8 months ago - GlobeNewsWire

Mesoblast to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in Edi...

8 months ago - GlobeNewsWire

Single Dose Of Mesoblast's Cell Therapy Shows Durable Reduction In Back Pain

Mesoblast Limited (NASDAQ: MESO) announced 36-month follow-up results from the 400-subject Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L in patients with chronic low back pain (CLBP) ass...

8 months ago - Benzinga

Single Dose of Mesoblast's Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patien...

36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase 36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase

8 months ago - GlobeNewsWire

FDA's Office Agrees On 12-Month Reduction In Pain As Primary Endpoint For Mesoblast's Back Pain Study

Mesoblast Limited (NASDAQ: MESO) received feedback from the FDA's Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients. The trial is assessing rexlemest...

9 months ago - Benzinga

FDA's OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received feedb...

9 months ago - GlobeNewsWire

Down 35.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Mesoblast Limited (MESO)

The heavy selling pressure might have exhausted for Mesoblast Limited (MESO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana...

9 months ago - Zacks Investment Research

Why Mesoblast Shares Are Falling

Mesoblast Limited (NASDAQ: MESO) shares are trading lower after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing. Mesoblast said the com...

9 months ago - Benzinga

Update on Novartis Agreement

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it has...

9 months ago - GlobeNewsWire

Mesoblast's Heart Failure Candidate Shows Treatment Benefit In High-Risk Patients

Mesoblast Limited (NASDAQ: MESO) announced new analyses from the landmark DREAM-HF Phase 3 trial of rexlemestrocel-L in HFrEF patients with diabetes and/or ischemia who are at high risk of cardiovascula...

9 months ago - Benzinga

Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure P...

Endpoint in Line with FDA Guidance on Key Outcomes in High-Risk Patients and with Pharma Industry Drugs Approved for Cardiovascular Risk Reduction in Diabetes Endpoint in Line with FDA Guidance on Key O...

9 months ago - GlobeNewsWire

Mesoblast Limited (MESO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

10 months ago - Zacks Investment Research

Wall Street Analysts Believe Mesoblast Limited (MESO) Could Rally 157%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 156.9% in Mesoblast Limited (MESO). While the effectiveness of this highly sought-after metric is questionable, t...

10 months ago - Zacks Investment Research

Operational Highlights and Financial Results for the Period Ended September 30, 2021

NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and ...

10 months ago - GlobeNewsWire